aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in San Diego, TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel targeted therapeutics for cancer and age-related diseases. The company's core mission is to address unmet medical needs by leveraging endoglin biology to create antibodies that bind to the endoglin receptor. TRACON's lead product candidate, envafolimab, is a PD-L1 antibody aimed at treating sarcoma, positioning the company within the oncology and age-related disease markets.
TRACON Pharmaceuticals has garnered attention through its innovative approach and strategic focus on targeted therapies. Notable figures affiliated with the company include its experienced leadership team and scientific advisors who bring extensive expertise in biopharmaceutical development. The company has achieved significant milestones, including advancing envafolimab through clinical trials. Overall, TRACON's impact lies in its potential to offer new therapeutic options for patients with cancer and other serious conditions, contributing to the advancement of medical science in these critical areas.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapeutics, Antibodies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Tracon Pharmaceuticals founded?
Tracon Pharmaceuticals was founded in 2004.
Where is Tracon Pharmaceuticals’s headquarters located?
Tracon Pharmaceuticals’s headquarters is located in San Diego, CA, US.
When was Tracon Pharmaceuticals’s last funding round?
Tracon Pharmaceuticals’s most recent funding round was for $30M (USD) in December 2022.
How many employees does Tracon Pharmaceuticals have?
Tracon Pharmaceuticals has 18 employees as of Feb 6, 2024.
How much has Tracon Pharmaceuticals raised to-date?
As of July 05, 2023, Tracon Pharmaceuticals has raised a total of $113M (USD) since Dec 27, 2022.
Add Comparison
Total Raised to Date
$113M
USD
Last Update Dec 27, 2022
Last Deal Details
$30M
USD
Dec 27, 2022
Post Ipo Debt
Total Employees Over Time
18
As of Feb 2024
Tracon Pharmaceuticals Address
4350 La Jolla Village Drive
suite 800
San Diego,
California
92122
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts